Just_Super/iStock via Getty Images
AbbVie’s Skyrizi gains pediatric psoriatic disease indication
kmk-vova/iStock via Getty Images
- The US FDA has approved AbbVie’s Skyrizi (risankizumab) for use in children six years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis.
- Approval was based on results from the phase 3 OptIMMize psoriasis clinical trial program.
- A 55 mg pre-filled syringe has also been approved for patients weighing less than 40 kg.